# Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma

Source: https://onco.cc/trials/nct05563922/  
OnCo record `nct05563922` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Shanghai Zhongshan Hospital, now recruiting.

## Summary

Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma is a phase 2, interventional study registered as NCT05563922 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 56 participants, started 2022-09-01 and due to reach its primary completion in 2025-08-31. Interventions recorded: Total Neoadjuvant Chemoradiotherapy. Conditions listed: Rectal Cancer. Primary outcome: Organ preservation rate at 3 years. Colorectal eligibility wording from the registry: "* cT1-3N0M0 assessed by CT, MRI and ultrasound colonoscopy". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: OP-TNT
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05563922
- Phase: 2
- Setting: Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Early Low Rectal Carcinoma: A Prospective, Exploratory Trial
- Sponsor: Shanghai Zhongshan Hospital
- Enrolled: 56

## Sources

- ClinicalTrials.gov NCT05563922: https://clinicaltrials.gov/study/NCT05563922

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05563922.json